Buy Thymosin Alpha-1 Peptide New Zealand
Thymosin alpha-1 (Tα1) is a 28-amino acid peptide first isolated from calf thymuses, called thymosin fraction 5. The peptide primarily functions as an immune system modulator, augmenting T-cell response, stimulating cytokine production, and enhancing the functional activities of natural killer cells. Consequently, Thymosin alpha-1 has found use in treating diseases associated with immune dysregulation.
In oncology, Thymosin alpha-1 has exhibited potential as an adjunctive therapy, bolstering the body’s immune response against tumor cells and thereby improving the effectiveness of conventional cancer treatments.
Shop our Full Range of Thymosin Alpha-1 Peptides
-
New Reduced Price
New Reduced Price
New Reduced Price
Thymosin Alpha-1 Nasal Spray
£64.25 – £123.50 This product has multiple variants. The options may be chosen on the product page -
Sale!
LL-37 Thymosin Alpha-1 Peptide
£85.58 – £94.56 This product has multiple variants. The options may be chosen on the product page -
Sale!
New Reduced Price
New Reduced Price
New Reduced Price
New Reduced Price
Thymosin Alpha1 10mg Pre Mixed
£58.83 – £158.84 This product has multiple variants. The options may be chosen on the product page -
New Reduced Price
New Reduced Price
New Reduced Price
Thymosin alpha-1
£56.25 – £191.25 This product has multiple variants. The options may be chosen on the product page
Thymosin Alpha-1 Mechanism Of Action
Thymosin Alpha-1 (Tα1) exhibits a multifaceted mechanism of action, primarily centred around its potent immunomodulatory properties. By interacting with several immune system components, Tα1 plays a critical role in enhancing the body’s natural defence mechanisms.
Interaction with Immune Cells
Tα1 engages with various immune cells, including T cells, dendritic cells, and natural killer (NK) cells, to modulate their activity. One of the key functions of Tα1 is to promote the maturation and differentiation of T cells, which are essential for adaptive immune responses. It increases the expression of markers and receptors on these cells, thereby enhancing their ability to respond to antigens and pathogens effectively.
Modulation of Cytokine Production
Tα1 influences cytokine production, notably enhancing the expression of interferons, such as interferon-α (IFN-α) and interferon-γ (IFN-γ). These cytokines are pivotal in antiviral responses and help in inhibiting viral replication. The upregulation of these critical cytokines by Tα1 thus positions it as a valuable therapeutic agent in treating viral infections and associated disorders.
Antioxidative and Anti-inflammatory Effects
Thymosin Alpha-1 also exerts antioxidative and anti-inflammatory effects, contributing to the regulation of oxidative stress and inflammation in the body. Through the modulation of oxidative stress markers and inflammatory pathways, Tα1 helps in mitigating cellular damage and controlling inflammatory responses, which is especially beneficial in chronic inflammatory and autoimmune conditions.
Enhancement of Antigen Presentation
In addition, Tα1 enhances the antigen-presenting capabilities of dendritic cells. By upregulating the presentation machinery, it ensures more efficient processing and presentation of antigens to T cells. This interaction is crucial for initiating robust and specific immune responses, facilitating the identification and destruction of infected or malignant cells.
Clinical Implications
Given these diverse mechanisms, Thymosin Alpha-1 studies have shown promising results in New Zealand clinical use, particularly in the treatment of chronic infections, malignancies, and immune deficiencies. Its ability to modulate immune responses makes it a versatile therapeutic agent with potential applications across various medical conditions.
Understanding the detailed mechanism of action of Thymosin Alpha-1 not only underscores its therapeutic potential but also facilitates its integration into clinical practice for improving New Zealand patient outcomes in immune-related diseases.
Source: PubChem
Structure of Thymosin Alpha-1
Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
Molecular Formula: C129H215N33O55
Molecular Weight: 3108.3 g/mol
PubChem CID: 16130571
What Are The Research Benefits of Thymosin Alpha-1?
Immune Modulation: Buy Thymosin Alpha-1 to enhance the immune system’s efficiency, making it a powerful tool for studying immune responses in various conditions. By boosting T-cell activity and promoting the production of cytokines, Tα1 helps improve the body’s ability to fight infections and may be beneficial in treating immune-related diseases.
Synergy with Antiretroviral Therapy: Thymosin Alpha-1 may offer synergistic benefits when used with antiretroviral therapy (ART) for treating HIV/AIDS. ART is the cornerstone of HIV treatment, reducing viral loads and improving patient outcomes. New Zealand Research suggests that Thymosin Alpha-1’s immunomodulatory properties can enhance immune function and resilience, aiding in viral suppression and reducing opportunistic infections. This combination warrants further investigation to optimize treatment strategies for HIV/AIDS patients, ensuring comprehensive care and improved quality of life.
Oncology Research: Its use as an adjunct in cancer immunotherapy can offer significant insights into improving treatment efficacy and patient outcomes. By enhancing the body’s immune response to target cancer cells more effectively, it holds the potential to revolutionize current therapeutic approaches and provide new hope for New Zealand patients battling various types of cancer.
Numerous New Zealand clinical studies have demonstrated promising outcomes for the use of thymosin alpha 1 in patients with metastatic melanoma, breast cancer, lung cancer, and hepatocellular carcinoma.
Autoimmune Disorders: New Zealand Research can examine its potential to modulate immune responses in autoimmune diseases, such as rheumatoid arthritis or lupus. This could lead to the development of novel therapeutic approaches that specifically target and regulate immune system activity, offering hope for more effective treatments.
Infectious Diseases: Studying Thymosin Alpha-1 could provide valuable data on combating chronic infections, enhancing immune system responses, and improving patient recovery times. This research may lead to new treatments for a variety of persistent infections, ultimately contributing to better overall health outcomes.
Vaccine Development: It may assist in enhancing the immune response to vaccines, leading to more effective immunisation strategies. This could result in higher efficacy rates, better protection against diseases, and potentially fewer doses needed to achieve immunity.
Anti-inflammatory Properties: Understanding its role in reducing inflammation can pave the way for novel treatments for various inflammatory conditions. By reducing oxidative damage in tissues, it safeguards against various diseases and enhancing general health. This could potentially lead to breakthroughs in managing chronic diseases such as arthritis, asthma, and even some cardiovascular issues, improving the quality of life for many individuals.
Cellular Mechanisms: Investigating how Thymosin Alpha-1 influences T-cell maturation and activity can uncover critical aspects of immune system functioning. This New Zealand research can provide insights into the pathways through which Thymosin Alpha-1 enhances immune responses, shedding light on potential therapeutic applications for immune-related disorders. Additionally, understanding these mechanisms may reveal new strategies for modulating immune activity in various diseases.
Combination Therapies: Research can focus on its synergistic effects when used alongside other treatments, such as chemotherapy or radiation, broadening therapeutic horizons and potentially enhancing patient outcomes. This approach could lead to more effective and personalized treatment plans.
Personalised Medicine: The study of Tα1 in different genetic backgrounds could support the development of more personalised treatment protocols by tailoring therapies to individual genetic profiles. This approach could improve treatment efficacy and reduce adverse effects, ultimately leading to better patient outcomes.
Buy Thymosin Alpha-1 New Zealand for research online today!
Buy Thymosin Alpha-1 and LL-37 (CAP-18) Peptide Stack
Buy Thymosin Alpha-1 10mg and LL-37 2mg peptide stack presented in sterile vials as lyophilized powder form for synergistic effects in immune modulation and infection control. Thymosin Alpha-1 (Ta-1) is a synthetic version of a natural thymic peptide that regulates and activates immune responses. Known for its strong immunomodulatory properties, Ta-1 enhances T-cell activity, promotes dendritic cell maturation, and stimulates cytokine production, making it crucial for managing viral infections, autoimmune diseases, and cancer.
LL-37, part of the human cathelicidin family, is a cationic antimicrobial peptide (CAMP) known for its broad-spectrum antimicrobial activity against bacteria, viruses, and fungi. LL-37 not only plays a critical role in the body’s innate immune defence by disrupting microbial membranes but also participates in wound healing, inflammation modulation, and the regulation of immune cell functions.
Buy Thymosin Alpha-1 Peptide Nasal Spray
Buy Thymosin Alpha-1 nasal spray, now available in 15ml and 30ml glass spray bottles at Direct Peptides New Zealand. Our high purity Ta-1 nasal spray is designed as an alternative to subcutaneous injections for efficient delivery through the nasal mucosa for rapid systemic effect.
Thymosin Alpha-1 nasal spray shows promise in various research areas, including immune modulation, vaccine enhancement, infectious disease combat, inflammatory condition treatment, and neurological studies. Its ease of administration is beneficial for both preclinical and clinical investigations, providing new avenues for exploring its effects on immune function, vaccine efficacy, antiviral properties, inflammation, and neuroprotection.
Frequently Asked Questions (FAQs) about Thymosin Alpha-1
What is Thymosin Alpha-1?
A peptide sequence consisting of 28 amino acids, Tα1 was first discovered in 1977. It is derived from prothymosin alpha, a protein encoded by the PTMA gene in humans, which is produced by stromal cells in the thymus gland. It is now used for its immunomodulatory properties. It enhances the body’s immune response by promoting the maturation and activity of T-cells, pivotal in defending against infections and regulating the immune system.
What are the primary uses of Thymosin Alpha-1?
Tα1 is primarily utilised in treating chronic infections, enhancing immune function, and as an adjunct therapy in cancer immunotherapy. It is also used in research settings to study its effects on immune modulation and autoimmune disorders.
How should Thymosin Alpha-1 be stored?
Tα1 peptide vial should be stored at -20°C to maintain its stability and efficacy. Once reconstituted, it should be used immediately. If not possible, it can be stored at 4°C for short periods, or aliquoted and frozen at -80°C for long-term storage, avoiding repeated freeze-thaw cycles.
Are there any side effects associated with Thymosin Alpha-1?
Thymosin Alpha-1 is generally well-tolerated, with minimal side effects. However, as with any therapeutic peptide, there may be potential for allergic reactions or site-specific discomfort depending on the delivery method. It is recommended to administer under professional guidance.
Can Thymosin Alpha-1 be used in combination with other treatments?
Yes, Tα1 can be used in combination with other therapies, especially in the context of cancer immunotherapy and treatments for chronic infections. As it modulates immune function, it can potentially enhance the efficacy of other treatments.
How quickly can one expect to see results from Thymosin Alpha-1?
The timeframe for observing results with Tα1 may vary based on individual conditions and the specific objectives of the research.
Some subjects might exhibit improvements within a few weeks, whereas long-term studies, particularly those focusing on chronic conditions or complex immune responses, might observe significant changes over several months.
Consistent administration, as outlined by research protocols and guided by healthcare professionals, is critical to achieve optimal outcomes and accurate data acquisition.
Is Thymosin Alpha-1 Legal?
You can buy Thymosin Alpha-1, also known as Zadaxin, legally for medical use in several countries, including the United States, where it has received legal approval from the US Food and Drug Administration (FDA) for certain indications such as in the treatment of hepatitis B and chronic hepatitis C, and as an adjunct therapy for cancer.
Classified under prescription drugs, its use is subject to regulatory controls that vary by country, ensuring that the peptide is dispensed as prescription medications through a licensed pharmacy. Tα1 from Direct Peptides is for research purposes only.
Healthcare providers must adhere to local regulations and guidelines when prescribing or administering Tα1 to ensure its safe and effective application for human consumption. In research settings, institutions often require ethical approvals and compliance with national and international research standards for development purposes, ensuring the peptide’s appropriate use in clinical trials and experimental studies.
For researchers looking to buy Thymosin Alpha-1, it is important to seek reputable sources that comply with regulatory standards. Direct Peptides ensures the product’s authenticity and quality, providing peace of mind for those concerned about safety and efficacy.
Summary of Research Applications
- Treatment for Sepsis: Research suggests Thymosin Alpha-1 (Tα1) has shown potential benefits in the treatment of sepsis. Specifically, it has been suggested that certain patient groups may be more likely to benefit from Tα1 immunotherapy [1], [2] and [3].
- Immune Modulation: According to research, Tα1 is noted for its immune-modulating properties. It has been found to have higher clinical benefit rates when used in conjunction with other treatments [4].
- Dental Applications: In studies, Tα1 has demonstrated both short-term and long-term benefits in the reimplantation of avulsed teeth [5].
- Broad Clinical Benefits: Since its first use in a clinical trial in 1985, a substantial amount of data has been produced supporting the potential clinical benefits of Tα1 [6].
- Cancer Therapy: Tα1 has been reappraised for its use in cancer therapy, with studies suggesting a higher clinical benefit rate and a trend towards its use in conjunction with other treatments [7].
- Treatment for Various Diseases: Research suggests the number of diseases that could potentially benefit from Tα1 treatment is growing, as it is a naturally occurring polypeptide [8].
- Treatment for Chronic Hepatitis B: Studies indicate the combined use of Tα1 and entecavir has shown benefits in the treatment of chronic hepatitis B [9].
- HIV-1 Treatment: Despite the consistent benefits for HIV-1 infected patients, more studies are needed concerning the use of Tα1 in HIV-1 infection [10].
Thymosin Alpha-1 Peptide Quality Assured
At Direct Peptides New Zealand, we elevate the benchmark for peptide solutions, providing Thymosin Alpha-1 peptides for sale that boast an impressive 99% purity.
Our rigorous synthesis protocols are meticulously crafted to ensure each batch meets and exceeds industry standards, reflecting our steadfast dedication to precision and excellence.
Whether you are looking to buy Thymosin Alpha-1 for your research needs, our unwavering commitment to superior purity not only solidifies our reputation for exceptional quality but also maximises the therapeutic efficacy of Thymosin Alpha-1.
View the High Performance Liquid Chromatography (HPLC) Certificate here.
References For Further Reading
[1] F.Pei, X.Guan, and J.Wu (2018) Thymosin alpha 1 treatment for patients with sepsis – Expert Opinion on Biological Therapy, Volume 18, 2018 – Issue sup1, Pages 71-76.
[2] C.Li, L.Bo, Q.Liu, and F.Jin (2015) – Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis – International Journal of Infectious Diseases, Volume 33, April 2015, Pages 90-96.
[3] J.Wu, L.Zhou, J.Liu, et al (2013) The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial – Critical Care, 2013 Jan 17, Volume 17 (Issue 1), R8.
[4] R.King, and C. Tuthill (2016) Chapter Seven – Immune Modulation with Thymosin Alpha 1 Treatment – Vitamins and Hormones, Volume 102, 2016, Pages 151-178.
[5] W.T.Y.Loo, Y.D.Dou, W.K.J.Chou, and M.Wang (2007) Thymosin alpha 1 provides short-term and long-term benefits in the reimplantation of avulsed teeth: a double-blind randomized control pilot study – The American Journal of Emergency Medicine, 2008 Jun;26(5):574-7.
[6] E.Garaci, C.Favalli, F.Pica, et al (2007) – Thymosin Alpha 1 – Annals of the New York Academy of Sciences, Volume 1112, Issue 1, Thymosins in Health and Disease First International Symposium, September 2007, Pages 225-234.
[7] C.Costantini, M.M.Bellet, M.Pariano, et al (2019) A Reappraisal of Thymosin Alpha1 in Cancer Therapy – Frontiers in Oncology, 06 September 2019, Sec. Cancer Immunity and Immunotherapy, Volume 9.
[8] F.Pica, R.Gaziano, I.A.Casalinuovo, et al (2018) Serum thymosin alpha 1 levels in normal and pathological conditions – Expert Opinion on Biological Therapy, 2018 Jul, Volume 18 (supplement 1), Pages 13-21.
[9] X.Wu, J.Jia, and H.You (2015) Thymosin alpha-1 treatment in chronic hepatitis B – Expert Opinion on Biological Therapy, Feb 2015, Volume 15, Issue Sup 1, Pages 129-132.
[10] C.Matteucci, S.Grelli, E.Balestrieri, et al (2017) Thymosin alpha 1 and HIV-1: recent advances and future perspectives – Future Microbiology, 2017 Feb, Volume 12, Pages 141-155.
[11] A.Dominari, D.Hathaway III, K.Pandav, et al (2020) Thymosin alpha 1: A comprehensive review of the literature – World Journal of Virology, 2020 Dec 15, Volume 9 (Issue 5), Pages 67–78.
Why Choose Direct Peptides New Zealand?
Discover unparalleled quality with Direct Peptides New Zealand, your leading provider of Tα1 peptides. What sets us apart is our exclusive selection of Tα1 formulations, offering everything from a 10mg peptide sterile vial to advanced peptide stacks designed for synergistic effects. Our range also includes peptide nasal sprays in both 15ml and 30ml options, along with pre-mixed peptide pens, ensuring that New Zealand researchers find the exact formulation they need for their specific projects. Buy Thymosin Alpha-1 confidently from Direct Peptides, knowing we also provide an assortment of peptide accessories, including bacteriostatic water, essential for the reconstitution of your peptides. Buy Thymosin Alpha-1 peptides online today!
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our New Zealand Direct Peptides website: https://new-zealand.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
Related Posts
Synergistic Power Of Peptide Stacks
A comprehensive look at the potential benefits of combining peptides in a stack to elevate their individual .
Is Your Immune System Weak?
Direct Peptides explores the benefits and applications of Thymosin Alpha-1 (Tα1) for enhancing immune function.
The Benefits Of Thymosin Alpha-1 In Treating Cystic Fibrosis
A closer look at how Thymosin Alpha-1 an immune modulator could potentially help treat cystic fibrosis.
